Stay updated with breaking news from Epigenetic Regulator Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DURECT Co. (NASDAQ:DRRX – Get Rating) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 565,100 shares, an increase of 39.9% from the May 15th total of 404,000 shares. Approximately 2.3% of the shares of the stock are short sold. […]
Equities researchers at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Rating) in a report released on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock. DRRX has been the subject of several other reports. Jonestrading started coverage on shares of DURECT in a research note on Tuesday, March […]
Tocqueville Asset Management L.P. lowered its stake in shares of DURECT Co. (NASDAQ:DRRX – Get Rating) by 89.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 91,240 shares of the specialty pharmaceutical company’s stock after selling 780,160 shares during the period. Tocqueville Asset Management L.P. owned approximately […]
DURECT Co. (NASDAQ:DRRX – Get Rating) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 362,400 shares, an increase of 6.6% from the April 15th total of 339,900 shares. Approximately 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of […]
DURECT Co. (NASDAQ:DRRX – Get Rating) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 362,400 shares, an increase of 6.6% from the April 15th total of 339,900 shares. Approximately 1.5% of the company’s shares are sold short. Based on […]